COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,051 Articles (22,627 medRxiv, 8,424 bioRxiv)

Most recent first Previous |  Page 548: Articles 5471-5480  | Next

Catch-up Routine Immunization to Restore Childhood Immunization Coverage following COVID-induced Declines in Zamboanga Peninsula, Philippines
Punzalan, M. G.
10.1101/2022.11.19.22282451 — Posted: 2022-11-21
Elevated circulating monocytes and monocyte activation in pulmonary post-acute sequelae of SARS-CoV-2 infection
Park, J., Dean, L. S., Jiyarom, B., Gangcuangco, L. M., Shah, P., Awamura, T., Ching, L. L., Nerurkar, V. R., Chow, D. C., Igno, F. R., Shikuma, C. M., Devendra, G.
10.1101/2022.11.19.22282543 — Posted: 2022-11-20
Oligosymptomatic long-term carriers of SARS-CoV-2 display impaired innate resistance and high Spike-specific neutralizing antibodies
Montes-Cobos, E., Bastos, V. C., Monteiro, C., Freitas, J. C., Fernandes, H. D., Constancio, C. S., Rodrigues, D. A., Gama, A. M., Vidal, V. M., Alves, L. S., Zalcberg-Renault, L., Lira, G. S., Ota, V. A., Caloba, C., Conde, L., Leitao, I. C., Tanuri, A., Ferreira, O. D., Pereira, R. M., Vale, A. M., Castineiras, T. M., Kaiserlian, D., Echevarria-Lima, J., Bozza, M. T.
10.1101/2022.11.19.22282546 — Posted: 2022-11-20
Immunogenicity and safety of a 4th homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2, randomized, placebo-controlled trial
Alves, K., Plested, J. S., Galbiati, S., Chau, G., Cloney-Clark, S., Zhu, M., Kalkeri, R., Patel, N., Smith, K., Marcheschi, A., Pfeiffer, S., McFall, H., Smith, G., Glenn, G. M., Dubovsky, F., Mallory, R. M.
10.1101/2022.11.18.22282414 — Posted: 2022-11-20
Excess mortality associated with the COVID-19 pandemic (2020-2021) in an urban community of Bangladesh: Evidence from cemetery-based death registration
Hossain, M. S., Khan, J. R., Mamun, S. A. A., Islam, M. T., Raheem, E.
10.1101/2022.11.19.22281995 — Posted: 2022-11-20
Changes in population immunity against infection and severe disease from SARS-CoV-2 Omicron variants in the United States between December 2021 and November 2022
Klaassen, F., Chitwood, M. H., Cohen, T., Pitzer, V. E., Russi, M., Swartwood, N. A., Salomon, J. A., Menzies, N. A.
10.1101/2022.11.19.22282525 — Posted: 2022-11-20
Serologic Responses to COVID-19 Vaccination in Children with History of Multisystem Inflammatory Syndrome (MIS-C)
Perez, M. A., Hsiao, H.-M., Chen, X., Kunkel, A., Baida, N., Hussaini, L., Lu, A. T., Kao, C. M., Laham, F. R., Hunstad, D. A., Beltran, Y., Hammett, T. A., Godfred-Cato, S., Chahroudi, A., Anderson, E. J., Belay, E., Rostad, C. A.
10.1101/2022.11.19.22282551 — Posted: 2022-11-20
Comparative analysis of pediatric Respiratory Syncytial Virus epidemiology and clinical severity before and during the COVID-19 pandemic in British Columbia, Canada
Vineta Paramo, M., Abu-Raya, B., Reicherz, F., Xu, R. Y., Bone, J. N., Srigley, J. A., Solimano, A., Goldfarb, D. M., Skowronski, D. M., Lavoie, P. M.
10.1101/2022.11.18.22282477 — Posted: 2022-11-19
Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters
Rescigno, M., Agrati, C., Salvarani, C., Giannarelli, D., Costantini, M., Mantovani, A., Massafra, R., Zinzani, P. L., Morrone, A., Notari, S., Matusali, G., Lauria Pinter, G., Uccelli, A., Ciliberto, G., Baldanti, F., Locatelli, F., Silvestris, N., Sinno, V., Turola, E., VAX4FRAIL study Group, , Lupo Stanghellini, M. T., Apolone, G.
10.1101/2022.11.19.22282537 — Posted: 2022-11-19
Running ahead of evolution - AI based simulation for predicting future high-risk SARS-CoV-2 variants
Chen, J., Nie, Z., Wang, Y., Wang, K., Xu, F., Hu, Z., Zheng, B., Wang, Z., Song, G., Zhang, J., Fu, J., Huang, X., Wang, Z., Ren, Z., Wang, Q., Li, D., Wei, D., zhou, B., Yang, C., Tian, Y.
10.1101/2022.11.17.516989 — Posted: 2022-11-19

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).